New Zealand markets open in 5 hours 5 minutes

MRNA Jan 2025 110.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
24.24-0.16 (-0.66%)
As of 09:37AM EDT. Market open.
Full screen
Previous close24.40
Expiry date2025-01-17
Day's range24.24 - 24.24
Contract rangeN/A
Open interest1.47k
  • Yahoo Finance Video

    Moderna CEO on combo Covid, flu vaccine moving to next trial phase

    A lot of Americans are planning on getting both a flu shot and Covid booster this fall. But Moderna (MRNA) has been working on a combination flu and Covid vaccine, so patients only need to get one shot instead of two. The biotech company announced that the combination vaccine will be moving on to its final trial after positive results from its early-stage trial. The company is hoping to have regulatory approval for the shot in 2025. Moderna CEO Stéphane Bancel tells Yahoo Finance Live that when it comes to it's current Covid vaccine, there has been "strong demand." Bancel expects to continue to see sales of the Covid vaccine into 2025 and "re-acceleration of sales" when the combination vaccine launches. When it comes to the current updated Covid booster, Bancel thinks that pharmacy chains may have underestimated demand for the shot and how quickly people would want it. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Yahoo Finance

    Novavax expects COVID-19 boosters to be available next week

    Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.

  • Zacks

    Alexandria (ARE) Expedites Delivery of Moderna's New HQ

    Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.